Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.55 |
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.55 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5334053 | 0.83 | CCNA2 (0.62) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL6791456 | 0.83 | CCNA2 (0.62) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5343708 | 0.83 | IKBKB (0.57) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5335768 | 0.81 | IKBKB (0.57) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5335359 | 0.80 | CCNA2 (0.58) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5338436 | 0.79 | IKBKB (0.55) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5347307 | 0.79 | CCNA2 (0.63) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5333595 | 0.78 | IKBKB (0.55) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5339056 | 0.78 | IKBKB (0.54) | IKBKBCCNA2CDK2CCNA1AURKA | |
| SCHEMBL5338246 | 0.78 | IKBKB (0.54) | IKBKBCCNA2CDK2CCNA1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | IKBKB 634/4885CCNA2 270/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.